A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET
EJNMMI Radiopharmacy and Chemistry, 2022 Background Pretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-lived PET isotopes, while reducing
Hugo Helbert +11 more
doaj +1 more source
89Zr-immuno-PET for imaging and quantification of biopharmaceuticals targeting neurodegenerative diseases [PDF]
Neurodegenerative diseases cost society over a trillion dollars annually. Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) are the two most prevalent diseases, affecting 50 million and 10 million individuals globally, respectively.
Wünsche, Thomas Erik
core +1 more source
Дизајн на физибилити студија за воспоставување на производство на zirconium-89 радиоизотоп и имплементација на 89Zr-радиофармацевтици во клиничката пракса во Република Северна Македонија [PDF]
, 2023 In the last decade, the application of radiopharmaceuticals based on zirconium-89 (89Zr) radiometal has increased in both preclinical and clinical studies.
Angelovska, Bistra +8 more
core +2 more sources
Good practices for 89Zr radiopharmaceutical production and quality control
EJNMMI Radiopharmacy and ChemistryBackground During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to its advantageous physical ...
Thomas Erik Wuensche +3 more
doaj +1 more source
Recent Advances in Zirconium-89 Chelator Development
Molecules, 2018 The interest in zirconium-89 (89Zr) as a positron-emitting radionuclide has grown considerably over the last decade due to its standardized production, long half-life of 78.2 h, favorable decay characteristics for positron emission tomography (PET ...
Nikunj B. Bhatt +2 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2020 Background Bispecific antibodies redirecting T cells to the tumor obtain increasing interest as potential cancer immunotherapy. ERY974, a full-length bispecific antibody targeting CD3ε on T cells and glypican 3 (GPC3) on tumors, has been in clinical ...
Stijn JH Waaijer +7 more
doaj +1 more source
Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. [PDF]
, 2017 The future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO).
Allott, L +6 more
core +1 more source
Guiding the development of multispecific antibody-based cancer immunotherapies with 89Zr-immuno-PET imaging [PDF]
Antibody-based checkpoint inhibitors improved the treatment of patients with several tumor types. Several antibodies targeting immune checkpoints have been approved for the treatment of patients with cancers.
van Winkel, Claudia
core +1 more source
Scientific Reports, 2021 The lack of a non-invasive test for malignant thyroid nodules makes the diagnosis of thyroid cancer (TC) challenging. Human galectin-3 (hGal3) has emerged as a promising target for medical TC imaging and diagnosis because of its exclusive overexpression ...
Emanuel Peplau +10 more
doaj +1 more source
Quantification of 89Zr-immunoPET:Methodological considerations. [PDF]
PURPOSE: Clinical 89Zr-immunoPET relies on semi-quantitative metrics, such as standardised uptake values (SUV) from static imaging at delayed time points. However, SUV can misinterpret target engagement as it ignores plasma and tissue kinetics.
Brouwers, Adrienne H +7 more
core +1 more source